Kardigan completed the acquisition of Prolaio.

Kardigan, a heart health company, completed the acquisition of Prolaio, a clinical intelligence company advancing cardiology research. Financial terms were not disclosed. “Kardigan and Prolaio were both founded to challenge the status quo in cardiology. If we have any shot at radically reducing the time and cost to develop meaningful new medicines and provide better healthcare for patients, biopharma companies today need to fundamentally embrace real-world data and AI-based tools in a way that is fully integrated across R&D. By taking a combined approach, we are paving the way to do something that both big pharma and big tech have struggled to successfully implement to date. Together, Kardigan and Prolaio represent a new and exciting type of company focused on heart health,” Tassos Gianakakos, Kardigan Co-Founder, CEO, and Chair.